KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Total Current Liabilities (2018 - 2025)

Historic Total Current Liabilities for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $83.4 million.

  • Adaptive Biotechnologies' Total Current Liabilities fell 486.84% to $83.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.4 million, marking a year-over-year decrease of 486.84%. This contributed to the annual value of $98.1 million for FY2024, which is 1140.49% up from last year.
  • Adaptive Biotechnologies' Total Current Liabilities amounted to $83.4 million in Q3 2025, which was down 486.84% from $92.1 million recorded in Q2 2025.
  • Adaptive Biotechnologies' 5-year Total Current Liabilities high stood at $122.4 million for Q3 2021, and its period low was $83.0 million during Q1 2024.
  • Its 5-year average for Total Current Liabilities is $99.3 million, with a median of $95.3 million in 2023.
  • In the last 5 years, Adaptive Biotechnologies' Total Current Liabilities surged by 3696.99% in 2021 and then crashed by 2169.62% in 2023.
  • Quarter analysis of 5 years shows Adaptive Biotechnologies' Total Current Liabilities stood at $113.8 million in 2021, then decreased by 3.53% to $109.8 million in 2022, then fell by 19.83% to $88.0 million in 2023, then grew by 11.4% to $98.1 million in 2024, then fell by 14.98% to $83.4 million in 2025.
  • Its Total Current Liabilities was $83.4 million in Q3 2025, compared to $92.1 million in Q2 2025 and $87.8 million in Q1 2025.